###begin article-title 0
Functional Analysis of a Dominant Negative Mutation of Interferon Regulatory Factor 5
###end article-title 0
###begin p 1
Conceived and designed the experiments: LY RL. Performed the experiments: LY TZ XS RL. Analyzed the data: LY RL. Wrote the paper: LY PN JH RL. Provided technical support: YW QS.
###end p 1
###begin title 2
Background
###end title 2
###begin p 3
Interferon regulatory factor (IRF) family members have been implicated as critical transcription factors that function in immune response, hematopoietic differentiation and cell growth regulation. Activation of IRF-5 results in the production of pro-inflammatory cytokines such as TNFalpha, IL6 and IL12p40, as well as type I interferons.
###end p 3
###begin title 4
Methodology/Principal Findings
###end title 4
###begin p 5
###xml 247 255 <span type="species:ncbi:9606">patients</span>
In this study, we identify a G202C (position relative to translation start codon) missense-mutation transcript of IRF-5 in transformed B and T cell lines, which were either infected or non-infected by viruses, and peripheral blood from ATL or CLL patients. The mutated transcript encodes a novel protein in which the sixty-eighth amino acid, Alanine, is substituted by Proline (IRF-5P68) in the DNA binding domain of IRF-5. IRF-5P68 phenotype results in a complete loss of its DNA-binding activity and functions as a dominant negative molecule through interacting with wild type IRF-5. Co-expression of IRF-5P68 inhibits MyD88-mediated IRF-5 transactivation. Moreover, Toll-like receptor (TLR)-dependent IL6 and IL12P40 production induced by lipopolysaccharide (LPS), R837 or CpG ODN 1826 was reduced in IRF-5 (P68) expressing cells as compared to the control cells.
###end p 5
###begin title 6
Conclusion
###end title 6
###begin p 7
###xml 236 244 <span type="species:ncbi:9606">patients</span>
IRF-5P68 acts as a dominant negative regulator that interferes with IRF-5-mediated production of pro-inflammatory cytokines. The functional characterization of the novel IRF-5 mutant in transformed B and T cell lines and in ATL and CLL patients may lead to a better understanding of the role of these transcriptional regulators in hematopoietic malignancies.
###end p 7
###begin title 8
Introduction
###end title 8
###begin p 9
###xml 285 288 285 288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Tamura1">[1]</xref>
###xml 290 293 290 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Hiscott1">[2]</xref>
###xml 464 467 464 467 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
###xml 469 472 469 472 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Paun1">[4]</xref>
###xml 474 477 474 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Takaoka1">[5]</xref>
###xml 479 482 479 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Hu1">[6]</xref>
###xml 620 623 620 623 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes1">[7]</xref>
###xml 625 628 625 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes2">[8]</xref>
###xml 630 633 630 633 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Mori1">[9]</xref>
###xml 798 801 798 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes2">[8]</xref>
###xml 1177 1181 1177 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Lin1">[10]</xref>
Biochemical, molecular biological and gene knockout studies have demonstrated that the members of the interferon regulatory factor family play important roles in pathogen response, cytokine signalling, hematopoietic differentiation, regulation of cell cycle and apoptosis (reviewed in [1], [2]. IRF-5 is involved in various activities, including activation of type I interferon and inflammatory cytokine gene expression and regulation of cell growth and apoptosis [3], [4], [5], [6]. Expression of IRF-5 has been detected in B cells and dendritic cells, and is further enhanced by type I IFN or the tumor suppressor p53 [7], [8], [9]. Two nuclear localization signals (NLS) have been identified in IRF-5, both of which are sufficient for nuclear translocation and retention in virus infected cells [8]. We have demonstrated that a CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization. IRF-5 possesses a functional nuclear export signal (NES) that controls dynamic shuttling between the cytoplasm and the nucleus. The NES element is dominant in unstimulated cells and results in the predominant cytoplasmic localization of IRF-5 [10].
###end p 9
###begin p 10
###xml 121 124 121 124 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Takaoka1">[5]</xref>
###xml 126 130 126 130 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Schoenemeyer1">[11]</xref>
###xml 393 397 393 397 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Honda1">[12]</xref>
###xml 603 607 603 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Balkhi1">[13]</xref>
###xml 823 826 819 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Takaoka1">[5]</xref>
###xml 828 832 824 828 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Schoenemeyer1">[11]</xref>
###xml 834 839 830 835 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IRF-5</italic>
###xml 1113 1116 1109 1112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Takaoka1">[5]</xref>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
Among the IRF family members, IRF-5 and IRF-7 share the same signaling pathway that is initiated through TLR7/8 and TLR9 [5], [11]. In response to TLR7/8 or TLR9 ligand, IRF-5 and IRF-7 are recruited to myeloid differentiation primary response gene (MyD) 88. Unlike IRF-7, which binds the death domain of MyD88, IRF-5 interacts with the intermediary domain and part of the TIR domain of MyD88 [12]. The MyD88-bound IRF-5 is activated by TNF receptor-associated factor (TRAF) 6 by an as-yet-unknown mechanism. A recent study demonstrated that IRF-5 is subject to TRAF6-mediated K63-linked ubiquitination [13]. Activated IRF-5 translocates to the nucleus, binds to the ISRE motifs in the promoter sequences and results in the production of pro-inflammatory cytokines such as TNFalpha, IL6 and IL12p40, as well as type I IFNs [5], [11]. IRF-5 knockout mice showed resistance to lethal shock induced by either unmethylated DNA or lipopolysaccharide, which correlates with a marked decrease in the serum levels of proinflammatory cytokines, and thus identifies IRF-5 as a key player in the TLR-Myd88 signaling pathway [5].
###end p 10
###begin p 11
###xml 6 11 6 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IRF-5</italic>
###xml 180 183 180 183 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
###xml 185 188 185 188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Paun1">[4]</xref>
###xml 301 304 301 304 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Takaoka1">[5]</xref>
###xml 502 505 502 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
###xml 507 510 507 510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Paun1">[4]</xref>
###xml 608 613 608 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IRF-5</italic>
###xml 629 637 629 637 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 637 640 637 640 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
###xml 779 782 779 782 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
###xml 925 928 925 928 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Paun1">[4]</xref>
###xml 26 30 <span type="species:ncbi:10090">mice</span>
###xml 296 300 <span type="species:ncbi:10090">mice</span>
###xml 315 338 <span type="species:ncbi:11176">Newcastle disease virus</span>
###xml 341 367 <span type="species:ncbi:11276">vesicular stomatitis virus</span>
###xml 372 399 <span type="species:ncbi:10298">herpes simplex virus type 1</span>
###xml 425 429 <span type="species:ncbi:10090">mice</span>
###xml 624 628 <span type="species:ncbi:10090">mice</span>
###xml 701 706 <span type="species:ncbi:10090">mouse</span>
###xml 757 761 <span type="species:ncbi:10090">mice</span>
Using IRF-5 gene-targeted mice, several groups have also shown that IRF-5 plays an important role in type I IFN production in a stimulation specific and cell type dependent manner [3], [4]. The induction of type I IFNs by various TLR ligands is normal in hematopoietic cells from IRF-5 deficient mice [5]. However, Newcastle disease virus-, vesicular stomatitis virus- or herpes simplex virus type 1-infected IRF-5 deficient mice have a significant decrease in the induction levels of serum type I IFN [3], [4]. The virus-mediated type I IFN production is also partially impaired in hematopoietic cells from IRF-5 deficient mice in vitro[3]. Interestingly, normal type I IFN induction was observed in mouse embryonic fibroblasts (MEFs) from IRF-5 deficient mice by these viruses [3]. Paun et al. also reported that TLR9, but not TLR3/4-mediated induction of type I IFN transcription, is dependent on IRF-5 in dendritic cells [4].
###end p 11
###begin p 12
###xml 148 152 148 152 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Honda2">[14]</xref>
###xml 357 365 357 365 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 370 377 370 377 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 377 380 377 380 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Mori1">[9]</xref>
###xml 382 386 382 386 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes3">[15]</xref>
###xml 523 526 523 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Hu1">[6]</xref>
###xml 528 531 528 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Mori1">[9]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes3">[15]</xref>
###xml 711 714 711 714 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
###xml 929 932 929 932 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bak</italic>
###xml 934 943 934 943 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">caspase 8</italic>
###xml 945 948 945 948 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bax</italic>
###xml 954 957 954 957 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21</italic>
###xml 957 961 957 961 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes3">[15]</xref>
###xml 1041 1044 1041 1044 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p21</italic>
###xml 1107 1112 1107 1112 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IRF-5</italic>
###xml 1220 1223 1220 1223 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
IRF family members have been implicated as critical transcription factors that function in cell growth regulation and hematopoietic differentiation [14]. The expression of IRF-5 is induced by viral infection through type I IFN signaling or by DNA damage through activated p53. As a direct p53 target gene, IRF-5 also inhibits the growth of tumor cells both in vitro and in vivo[9], [15]. IRF-5 can also inhibit B-cell lymphoma tumor growth and sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death [6], [9], [15]. Indeed, IRF-5 deficient MEFs showed a similar phenotype to p53 deficient MEFs in DNA damage-induced apoptosis, indicating that IRF-5 is essential to the apoptotic response [3]. Barnes et al. reported that IRF-5 mediated growth inhibition is associated with a p53-independent G2-M cell cycle arrest and with the stimulation of multiple cell cycle regulatory and proapoptotic genes including Bak, caspase 8, Bax, and p21[15]. In contrast, the study from Taniguchi's group indicates that the induction of p21 gene and the induction of cell cycle arrest normally occur in IRF-5 deficient cells. They suggest that IRF-5 is selectively involved in apoptosis but not in cell cycle arrest [3].
###end p 12
###begin p 13
###xml 287 295 <span type="species:ncbi:9606">patients</span>
###xml 549 554 <span type="species:ncbi:9606">human</span>
In this study, we identified a G202C (position relative to start codon) missense mutation (Ala68Pro) in DNA binding domain of IRF-5 (IRF-5(P68) in tumor or transform B and T cell lines and peripheral blood from chronic lymphocytic leukemia (CLL) and adult T-cell leukemia/lymphoma (ATL) patients. The IRF-5 (P68) functions as a dominant negative molecule through interacting with wildtype IRF-5, and leading to the inhibition of IRF-5 DNA binding and transactivation activity. It will be of great interest to examine the status of IRF-5 mutation in human cancers and the role of this mutation on cell growth and apoptosis.
###end p 13
###begin title 14
Materials and Methods
###end title 14
###begin title 15
Ethics Statement
###end title 15
###begin p 16
###xml 136 144 <span type="species:ncbi:9606">patients</span>
This study was approved by the Research Ethics Committee of the SMBD-Jewish General Hospital (Federalwide Assurance Number: 0796). Four patients with a diagnosis of B-CLL followed at the Jewish General Hospital of Montreal were recruited in the study after informed consent.
###end p 16
###begin title 17
Plasmid constructions
###end title 17
###begin p 18
###xml 199 203 199 203 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Lin1">[10]</xref>
###xml 205 209 205 209 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Lin2">[16]</xref>
###xml 211 216 <span type="species:ncbi:9606">Human</span>
Plasmids encoding GFP-IRF-5 (variant 1), Flag-IRF-5 (variant 1), Flag-IRF-5(4D) (variant 1), Myc-IRF-5 (variant 1), IRF-3(1-133)/pGEX-4T-2, IRF-7(1-150)/pGEX-4T-2 and pRLTK were described previously [10], [16]. Human IRF-5P68 cDNA (variant 1) was amplified by RT-PCR from Namalwa B-cell line and cloned into myc pcDNA3.1/Zeo (Myc-IRF-5P68) and pEGFP-C1 (GFP-IRF-5P68). GFP-IRF-5 pMSCV puro and GFP-IRF-5P68 pmscv puro were generated by cloning the AgeI-BamHI fragment (filled in with Klenow enzyme) from GFP-IRF-5 and GFP-IRF-5P68 into the BglII site (filled in with Klenow enzyme) of the pMSCV puro vector (Clontech). IRF-5(1-130)/pGEX-4T-2 and IRF-5P68 (1-130)/pGEX-4T-2 were generated by PCR and cloned into pGEX-4T-2 vector. The IL12p40-pGL3 was kindly gifted by Dr. Keiko Ozato (NICHD, Bethesda, MD, USA).
###end p 18
###begin title 19
Generation of stable cell lines and immunoblot analysis
###end title 19
###begin p 20
###xml 221 226 <span type="species:ncbi:9606">human</span>
###xml 380 386 <span type="species:ncbi:9913">bovine</span>
###xml 1160 1164 <span type="species:ncbi:9925">goat</span>
###xml 1169 1174 <span type="species:ncbi:10090">mouse</span>
Infectious retroparticles encoding either IRF-5P68 fused with GFP or GFP alone were generated with 293-GP2 packaging cell (Clontech, Mountain View, CA) and concentrated retroparticles were used to gene modify RAW264.7 or human embryonic kidney (HEK)293 cells. The monoclonal cell lines were selected by 4 ug/ml of puromycine in RPMI 1640 (Wisent Inc.) supplemented with 10% fetal bovine serum, sodium pyruvate and antibiotics. To determine the expression of the transgenes, equivalent amounts of whole cell extract (20 microg) were subjected to SDS-polyacrylamide gel electrophoresis (PAGE) with 10% polyacrylamide. After electrophoresis, proteins were transferred to a Hybond transfer membrane (Amersham) in a buffer containing 30 mM Tris, 200 mM glycine, and 20% methanol for 1 h. The membrane was blocked by incubation in phosphate-buffered saline (PBS) containing 5% dried milk for 1 h and then probed with anti-GFP antibody (Roche) in 5% milk-PBS at a dilution of 1:2000. These incubations were done at 4degreesC overnight or at room temperature for 1 h. After three 10-min washes with PBS, the membrane was reacted with a peroxidase-conjugated secondary goat ant-mouse antibody (Amersham Corp.) at a dilution of 1:5000. The reaction was then vsualized with an enhanced chemiluminescence detection system as recommended by the manufacturer (Amersham).
###end p 20
###begin title 21
DNA Sequencing
###end title 21
###begin p 22
###xml 475 476 475 476 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 674 677 674 677 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Eco</italic>
###xml 681 684 681 684 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bam</italic>
###xml 834 868 834 868 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GATCGAATTCCTCTGCCATGAACCAGTCCA3&#8242;</named-content>
###xml 873 906 873 906 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GATGGATCCGACCTCGTAGATCTTGTAGG3&#8242;</named-content>
###xml 45 53 <span type="species:ncbi:9606">patients</span>
###xml 187 195 <span type="species:ncbi:9606">patients</span>
Peripheral blood lymphocyte samples from ATL patients and normal donors were obtained from Dr Nazli Azimi (NCI, Bethesda, MD, USA). Total RNA was isolated from PBMCs obtained from either patients or healthy donors using the QIAGEN RNeasy MiniKit. The total RNA from T cell lines (CEM, Jukart) and B cell lines (Namalwa, Mc-KAR, BJAB and BC-3) were kindly gifted by John Hiscott's lab. Those total RNAs were then subjected to reverse transcription using SuperScript II, RNAseH- reverse transcriptase (Invitrogen) according to manufacturer's instructions. The cDNAs either from reverse transcription or cDNA library were amplified by PCR. The products were then digested with Eco RI/Bam HI and cloned into pBluescript KS (+). Plasmid DNA were isolated from individual clone and subjected to sequence analysis. The primers for PCR were: 5'GATCGAATTCCTCTGCCATGAACCAGTCCA3' and 5'GATGGATCCGACCTCGTAGATCTTGTAGG3'.
###end p 22
###begin title 23
Protein expression and purification
###end title 23
###begin p 24
###xml 16 17 16 17 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 130 136 130 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">E.coli</italic>
###xml 130 136 <span type="species:ncbi:110766|species:ncbi:562">E.coli</span>
The glutathione S-transferase (GST)-IRF-3, GST-IRF-5, GST-IRF-5P68 and GST-IRF-7 fusion proteins were expressed and isolated from E.coli DH5alpha following a 3 h induction with 1 mM IPTG (Pharmacia) at 37degreesC. Bacterial extracts in PBS containing 1% Triton X-100 were incubated with glutathione sepharose beads (Pharmacia) for 20 min at room temperature. After washed three times with PBS, the fusion proteins were eluted with 15 mM GSH in PBS.
###end p 24
###begin title 25
Electromobility shift assay (EMSA)
###end title 25
###begin p 26
###xml 585 587 561 563 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 709 714 685 690 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">ISG15</italic>
###xml 725 758 701 734 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;GATCGGAAAGGGAAACCGAAACTGAAGCC3&#8242;</named-content>
###xml 1415 1417 1373 1375 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
Whole cell extracts were prepared 24 h after transfection with expression plasmids. Cells were washed with phosphate buffered saline (PBS) and lysed in 10 mM Tris-Cl (pH 8.0), 60 mM KCL, 1 mM EDTA, 1 mM DTT, 0.5% NP-40, 0.5 mM phenylmethylsulfonyl fluoride (PMSF), leupeptin (10 microg/ml), pepstatin (10 microg/ml), aprotinin (10 microg/ml), chymostatin (0.5 microg/ml), and 0.25 microM microcystin. Equivalent amounts of whole-cell extract (20 microg) or various amounts of recombinant proteins were assayed for IRF-3, IRF-5, IRF-5P68 and IRF-7 binding by gel shift analysis using a 32P-labled double-stranded oligonucleotide corresponding to the interferon stimulated response element (ISRE) region of the ISG15 promoter (5'GATCGGAAAGGGAAACCGAAACTGAAGCC3'). The binding mixture (20 microl) contained 10 mM Tris-HCl (pH 7.5), 1 mM EDTA, 50 mM NaCl, 2 mM DTT, 5% glycerol, 0.5% NP-40, 10 microg/ml of BSA, and 62.5 microg/ml of poly(dI-dC) was added to reduce non-specific binding. After 20 min of incubation with the probe, extracts were loaded on a 5% polyacrylamide gel (60:1 cross-link) prepared in 0.5 X TBE. After 2 h electrophoresis at 200 to 250 V, the gel was dried and exposed to Kodak film at -70degreesC overnight. To demonstrate the specificity of protein-DNA complex formation, either a 100-fold molar excess of unlabled oligonucleotide or anti-Flag antibody were added to the binding mixture before 32P-labled probe was added.
###end p 26
###begin title 27
Luciferase assay
###end title 27
###begin p 28
###xml 179 186 179 186 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Renilla</italic>
###xml 535 537 535 537 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TM</sup>
Transfections for luciferase assay were carried out in either HEK293 cells or RAW264.7 cells. Subconfluent 293 cells were transiently co-transfected with 50 ng of pRLTK reporter (Renilla luciferase for internal control), 100 ng of pGL-3 reporter (firefly luciferase, experimental reporter) and IRF-5, IRF-5P68 and MyD88 by calcium phosphate co-precipitation method. RAW264.7 cells seeded on 6-well plates were transfected with 100 ng of pRLTK reporter, 200 ng of pGL-3 reporter and IRF-5, IRF-5P68 and MyD88 by using lipofectamine 2000TM according to the manufacturer's instructions (Invitrogen). The reporter plasmid was IL12p40 pGL-3 reporter gene. The total amounts of DNA were kept constant by supplementation with an empty vector (pcDNA3.1). At 24 h after transfection, the reporter gene activities were measured by dual-luciferase reporter assay, according to the manufacturer's instructions (Promega).
###end p 28
###begin title 29
Analysis of protein-protein interactions
###end title 29
###begin p 30
HEK293 cells were transfected with expression plasmids. Whole-cell extracts (300 microg) were prepared from transfected cells and were incubated for 1 h at 4degreesC with 1 microg anti-Flag (M2; Sigma-Aldrich) or anti-GFP (Roche) crosslinked to 100 microl protein A/G PLUS-Agarose (Santa Cruz Biotechnology). Precipitants were washed five times with lysis buffer and proteins were eluted by boiling the beads for 3 min in 1x SDS sample buffer. Eluted proteins or 5% of the input whole cell extracts were separated by 10% SDS-PAGE. After electrophoresis, proteins were transferred for 1 h to Hybond transfer membrances (Amersham) in a buffer containing 30 mM Tris, 200 mM glycine and 20% (vol/vol) methanol. Membranes were blocked by incubation for 1h in PBS containing 5% (wt/vol) dried milk and then were probed with anti-GFP, anti-Myc (9E10; Sigma-Aldrich) or anti-Flag, each at a concentration of 1 ug/ml. Immunocomplexes were detected with a chemiluminescence-based system (ECL; Amersham).
###end p 30
###begin title 31
RT-PCR
###end title 31
###begin p 32
###xml 197 198 193 194 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;</sup>
###xml 292 295 288 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 323 327 319 323 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLIP</italic>
###xml 333 337 329 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IKBA</italic>
###xml 356 360 352 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Negishi1">[17]</xref>
###xml 365 370 361 366 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
###xml 374 378 370 374 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Zhao1">[18]</xref>
###xml 396 400 392 396 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 410 439 406 435 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;- TTATGTTGTAGAGGTGGACTGG-3&#8242;</named-content>
###xml 444 472 440 468 <named-content xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" content-type="gene">5&#8242;-TTTCTTTGCACCAGCCATGAGC-3&#8242;</named-content>
Total RNA ( microg), isolated from monoclonal RAW264.7 cells stably carrying GFP-IRF-5P68 or GFP using the QIAGEN RNeasy MiniKit, was subjected to reverse transcription using SuperScript II, RNAseH- reverse transcriptase (Invitrogen) according to manufacturer's instructions. The primers for IL6, FLICE-inhibitory protein (FLIP) and IKBA were described in [17] and GAPDH in [18]. The primers for IL12p40 were: 5'- TTATGTTGTAGAGGTGGACTGG-3' and 5'-TTTCTTTGCACCAGCCATGAGC-3'. One microliters of the obtained cDNA was then amplified by PCR using Taq polymerase (Amersham) as per manufacturer's instructions. PCR conditions were as follows for all primers: 94degreesC for 3 min, cycles: 94degreesC for 45 sec, 56degreesC for 45 sec, and 72degreesC for 1 min, 22-30 times depending on optimal product detection, 72degreesC for 7 min. PCR samples were then resolved in a 2% agarose gel and visualized by Ethidium Bromide staining under UV light.
###end p 32
###begin title 33
Enzyme-linked immunosorbent assay (ELISA)
###end title 33
###begin p 34
Monoclonal RAW264.7 cells stably carrying GFP-IRF-5P68 or GFP were mock treated (-) or treated with LPS (Sigma-Aldrich), R837 or CpG ODN 1826 (Invivogen) for 24 h. IL6 and IL12p40 were measured by ELISA according to the manufacturer's instructions (PBL biomedical laboratories and R&D system, respectively).
###end p 34
###begin title 35
Results
###end title 35
###begin title 36
Characterization of an IRF-5 mutant
###end title 36
###begin p 37
###xml 103 106 103 106 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes1">[7]</xref>
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes4">[19]</xref>
###xml 509 516 509 516 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 1</bold>
###xml 509 516 509 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005500-t001"><bold>Table 1</bold></xref>
###xml 132 137 <span type="species:ncbi:9606">human</span>
###xml 378 412 <span type="species:ncbi:11908">Human T-cell leukemia virus type 1</span>
IRF-5 is predominantly expressed in lymphoid cells such as T cells, B cells, monocytes and macrophages [7], [19]. While cloning the human IRF-5 gene from a T cell cDNA library, we found a G202C missense mutation that resulted in an Ala 68 Pro mutated form of IRF-5 (referred to as IRF-5P68). To confirm the existence of this mutant, we sequenced the IRF-5 cDNA amplified from a Human T-cell leukemia virus type 1-infected T cell cDNA library and an EBV-infected B cell cDNA library, respectively. As shown in Table 1, the mutation was detected in both cDNA libraries and the ratio of mutation was significant. We then isolated total RNAs from a number of transformed T cell lines and B cell lines and performed sequencing. The same mutation was identified in both T cell lines (CEM and Jurkat) and B cell lines (Namalwa, Mc-KAR, BJAB and BC-3). Interestingly, both virus-infected and non-infected cell lines carried this mutation. These results raised the possibility that this mutation is associated with some malignant diseases, and unlikely derived from viral infection.
###end p 37
###begin title 38
Identification of Ala to Pro mutation in residue 68 of IRF-5 from cDNA library and cell lines.
###end title 38
###begin p 39
IRF-5 cDNA was PCR amplified from cDNA library or RT-PCR amplified with RNA isolated from indicated cell lines and cloned into Bluescript vector. Frequency of mutation was determined by DNA sequencing from plasmid DNA isolated from each sample.
###end p 39
###begin p 40
###xml 424 431 424 431 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table 2</bold>
###xml 424 431 424 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pone-0005500-t002"><bold>Table 2</bold></xref>
###xml 158 166 <span type="species:ncbi:9606">patients</span>
###xml 450 458 <span type="species:ncbi:9606">patients</span>
To further characterize the link between this mutation and leukemic diseases, we sequenced the RNA samples obtained from peripheral blood monocytes (PBMC) of patients suffering from adult T-cell leukemia/lymphoma (ATL) and chronic lymphocytic leukemia (CLL) and healthy donors as a control. The pathogenesis of ATL results from HTLV-1 infection, while the pathogenesis of CLL is not relevant to viral infection. As shown in Table 2, both ATL and CLL patients carried this mutant, but healthy donors not. This reveals that the IRF-5 mutation is probably linked to ATL or CLL.
###end p 40
###begin title 41
###xml 94 102 <span type="species:ncbi:9606">patients</span>
Identification of Ala to Pro mutation in residue 68 of IRF-5 from peripheral blood of ALL/CLL patients.
###end title 41
###begin p 42
###xml 80 88 <span type="species:ncbi:9606">patients</span>
IRF-5 cDNA was PCR amplified from peripheral blood of healthy donors or ALL/CLL patients and cloned into Bluescript vector. Frequency of mutation was determined by DNA sequencing from plasmid DNA isolated from each sample.
###end p 42
###begin title 43
IRF-5P68 does not possess DNA binding activity
###end title 43
###begin p 44
###xml 335 342 335 342 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1A</bold>
###xml 335 342 335 342 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g001"><bold>Fig. 1A</bold></xref>
###xml 570 571 570 571 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">S</italic>
###xml 890 897 890 897 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1B</bold>
###xml 890 897 890 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g001"><bold>Fig. 1B</bold></xref>
###xml 1207 1214 1207 1214 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1C</bold>
###xml 1207 1214 1207 1214 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g001"><bold>Fig. 1C</bold></xref>
Like other IRF family members such as IRF-3 and IRF-7, IRF-5 is also characterized as a trans-activator, which contains an N-terminal DNA-binding domain and a C-terminal trans-activation domain. Given that the mutation site occurs within the N-terminal DNA-binding domain of IRF-5, we thus adopted bioinformatics analysis. As shown in Fig. 1A, the mutation is located in the flanking site of consensus sequence of IRF family member. We therefore hypothesized that the point mutation may ablate its DNA-binding activity. To test this hypothesis, we generated glutathione S-transferase (GST) tagged recombinant N-terminal DNA-binding domain of IRF-5 (referred to as GST-IRF-5), IRF-5P68 (referred to as GST-IRF-5P68), IRF-3 (referred to as GST-IRF-3) and IRF-7 (referred to as GST-IRF-7), respectively. The purity of these recombinant proteins was monitored by coomassie blue staining assay (Fig. 1B), and then subjected to electropheresis mobility shift assay (EMSA). The GST-IRF-3, GST-IRF-5 and GST-IRF-7 formed protein-DNA complex with the IFN-stimulated response element (ISRE) in a dose-dependent manner. In contrast, the formation of protein-DNA complex between GST-IRF-5P68 and ISRE was not detected (Fig. 1C). These data indicated that this missense mutation abrogates the DNA-binding activity of IRF-5P68.
###end p 44
###begin title 45
IRF-5P68 does not possess DNA binding activity.
###end title 45
###begin p 46
###xml 232 234 232 234 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
###xml 63 68 <span type="species:ncbi:9606">human</span>
(A) Sequence alignment of the N-terminal DNA binding domain of human IRF members. (B) Coomassie staining of recombinant GST-tagged N-terminal IRF-3, IRF-5, IRF-5P68 and IRF-7. (C) EMSA of recombinant protein from a incubated with a 32P-labeled probe corresponding to the ISRE motif from the promoter of the gene encoding the ubiquitin-like modifier ISG15. (C) Representative green fluorescence images of living cells stably expressing IRF-5 and IRF-5P68 fused to GFP (top). The subcellular localization of the GFP-IRF-5 and GFP-IRF-5P68 was analyzed in untreated and leptomycin B-treated HEK 293 and RAW 264.7 cells. GFP fluorescence was analyzed in living cells with an Olympus BX51 fluorescence microscope using a X 40 objective. Bottom, immunoblot analysis is of GFP-IRF-5 and GFP-IRF-5P68 expression, and the expression of GFP alone as a control.
###end p 46
###begin p 47
###xml 589 603 589 603 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">data not shown</bold>
###xml 345 350 <span type="species:ncbi:10090">mouse</span>
It is reported that in unstimulated cells IRF-5 predominantly resides in the cytoplasm, and dynamically shuttles between nucleus and cytoplasm. To investigate whether this point mutation changes IRF-5 subcellular localization, wild type and point-mutated form of IRF-5 were linked to GFP, stably tansfected into HEK293 cells and RAW264.7 cells (mouse leukemic monocyte macrophage cell line), and examined for leptomycin B (LMB)-induced changes in subcellular localization. Like its counterpart IRF-5 wild type, the major proportion of IRF-5P68 localized in the cytoplasm of resting cells (data not shown). Treatment with LMB, a CRM1 inhibitor, resulted in predominant nuclear accumulation of IRF-5P68. These results suggest that this point mutation does not markedly alter IRF-5P68 protein localization in comparison with wild-type IRF-5 in resting cells.
###end p 47
###begin title 48
IRF-5P68 inhibits IRF-5-mediated transactivation activity
###end title 48
###begin p 49
###xml 286 290 282 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 304 308 300 304 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 359 366 355 362 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2A</bold>
###xml 359 366 355 362 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g002"><bold>Fig. 2A</bold></xref>
###xml 511 515 507 511 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 631 638 627 634 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2B</bold>
###xml 631 638 627 634 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g002"><bold>Fig. 2B</bold></xref>
IRF-5, as a transactivator, is a central mediator in the regulation of proinflammatory cytokines, such as TNF-alpha, IL6 and IL12p40. To examine the involvement of IRF-5P68 in the IRF-5-mediated transactivation activity, we measured expression of luciferase reporter gene driven by the IL12p40 promoter (IL12p40-luc) in HEK293 and RAW264.7 cells. As shown in Fig. 2A, in both cell lines, the IL12p40 promoter activity was effectively induced by wild type IRF-5, but not IRF-5P68. Unexpectedly, the induction of IL12p40 promoter activity by wild type IRF-5 was markedly decreased with the increasing amounts of IRF-5P68 expression (Fig. 2B). These findings suggest that IRF-5P68 might negatively regulate IRF-5 transactivation activity.
###end p 49
###begin title 50
IRF-5P68 negatively regulates wild type IRF-5 transactivation activity.
###end title 50
###begin p 51
###xml 70 74 70 74 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 412 416 412 416 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 754 758 754 758 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
(A) HEK293 cells were transfected with pRLTK control plasmid (50 ng), IL12p40-luc reporter plasmid (100 ng) and IRF-5-expressing plasmid (200 ng) together with an increase amount of IRF-5P68 expression plasmid (0, 40, 200 and 1000 ng) as indicated. Immunoblot analysis of whole cell lysates prepared for luciferase assay was showed (right). (B) RAW264.7 cells were trasfected with pRLTK control plasmid (100ng), IL12p40-luc reporter plasmid (200 ng) and IRF-5-expressing plasmid (400 ng) together with an increase amount of IRF-5P68 expression plasmid (0, 80, 400 and 2000 ng) as indicated. Immunoblot analysis of whole cell lysates prepared for luciferase assay was showed (right). (C) RAW264.7 cells were trasfected with pRLTK control plasmid (100ng), IL12p40-luc reporter plasmid (200 ng), MyD88- and IRF-5-expressing plasmid (300 ng) together with an increase amount of IRF-5P68 expression plasmid (0, 300, 900 and 1800 ng) as indicated. Immunoblot analysis of whole cell lysates prepared for luciferase assay was showed (right). In all transfections, the pcDNA3 vector was added to bring the total plasmid to the same amount. Luciferase activity was analyzed at 24-h post-transfection by the Dual-Luciferase Reporter assay as described by the manufacturer (Promega). Relative luciferase activity was measured as-fold activation (relative to the basal level of reporter gene in the presence of pcDNA3 vector after normalization with co-transfected RLU activity); values are mean +/- S.D. for three experiments.
###end p 51
###begin p 52
###xml 241 248 241 248 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 2C</bold>
###xml 241 248 241 248 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g002"><bold>Fig. 2C</bold></xref>
###xml 254 258 254 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
Because IRF-5 was characterized as a downstream component of TLR-MyD88- TNF receptor-associated factor (TRAF) 6 signalling, we next investigated whether the expression of IRF-5P68 interferes with MyD88-mediated IRF-5 activation. As shown in Fig. 2C, the IL12p40 promoter activity induced by MyD88 was markedly suppressed by IRF-5P68 in a dose-dependent manner. These results indicate that IRF-5P68 might participate in the modulation of TLR-signalling.
###end p 52
###begin title 53
IRF-5P68 interacts with wild-type IRF-5 and inhibited IRF-5 DNA binding activity
###end title 53
###begin p 54
###xml 151 155 151 155 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes5">[20]</xref>
###xml 472 479 472 479 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3A</bold>
###xml 472 479 472 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g003"><bold>Fig. 3A</bold></xref>
###xml 907 914 907 914 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3B</bold>
###xml 907 914 907 914 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g003"><bold>Fig. 3B</bold></xref>
IRF family members such as IRF-3, IRF-5 and IRF-7 can form either homo-or hetero-dimers. Dimerization is critical for the regulation of their activity [20]. These findings suggest that the IRF-5P68 may modulate wild type IRF-5 activity through intermolecular interactions between IRF-5P68 and wild type IRF-5. To test this possibility, we expressed GFP-tagged IRF-5P68 together with Flag-tagged IRF-5 in HEK293 cells and performed coimmunoprecipitation assay. As shown in Fig. 3A, GFP-tagged IRF-5P68 was coimmunoprecipitated with Flag-tagged IRF-5, and vice versa, Flag-tagged IRF-5 was coimmunoprecipitated with GFP-IRF-5P68. To elucidate the possibility that binding of IRF-5P68 to wild type IRF-5 blocks IRF-5 DNA binding activity, we expressed Flag-tagged IRF-5 and Myc-tagged IRF-5P68 either alone or together into HEK293 cells, and then subjected to electrophoresis mobility-shift assay. As shown in Fig. 3B, Flag-tagged IRF-5 alone but not Myc-IRF-5P68 bound to ISRE DNA probe. This observation is consistent with previous data showing that GST-IRF-5 bound to ISRE whereas IRF-5P68 did not. Intriguingly, when coexpressed with Myc-IRF-5P68, the DNA-binding activity of Flag-IRF-5 was strikingly compromised. These observations indicate that IRF-5P68 can dimerize with wild type IRF-5 and inhibit IRF-5 DNA-binding activity.
###end p 54
###begin title 55
IRF-5P68 interacts with wild-type IRF-5 and inhibits IRF-5 DNA binding activity.
###end title 55
###begin p 56
###xml 548 550 544 546 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">32</sup>
(A) HEK293 cells were transfected with expression plasmids as indicated above the lanes. At 24 h post-transfection, Flag-tagged or GFP-tagged proteins were immunoprecipitated, separated by SDS-PAGE and probed with indicated antibodies. Whole cell extracts (WCE) were also separated SDS-PAGE and probed with antibodies as indicated. (B) HEK293 cells were transfected with expression plasmids as indicated (IRF-5WT: Flag-tagged; IRF-5P68: Myc-tagged). EMSA was performed with whole cell extracts (30 microg) derived from transfected HEK293 cells and 32P-labelled probe corresponds to the ISRE of the ISG-15 gene (left). Immunoblot analysis of whole cell extracts prepared for EMSA was showed (right). (C) HEK293 cells were transfected with expression plasmids as indicated above the lanes. At 24 h post-transfection, Flag-tagged proteins were immunoprecipitated, separated by SDS-PAGE and probed with indicated antibodies. Whole cell extracts (WCE) were also separated SDS-PAGE and probed with antibodies as indicated.
###end p 56
###begin p 57
###xml 424 431 424 431 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 3C</bold>
###xml 424 431 424 431 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g003"><bold>Fig. 3C</bold></xref>
Because the IRF-5 mutant can interact with wild type IRF-5, it should compete with wild-type IRF-5 for dimerization so as to interfere with the formation of IRF-5 dimers. To test this possibility, we expressed fixed amounts of the Flag-tagged IRF-5 and Myc-tagged IRF-5 together with increasing amounts of GFP-tagged IRF-5P68 into HEK293 cells and monitored IRF-5 dimerization by coimmunoprecipitation analysis. As shown in Fig. 3C, IRF-5P68 inhibited IRF-5 dimerization in a dose-dependent manner. These data suggest that IRF-5P68 interferes with the formation of IRF-5 homodimer.
###end p 57
###begin title 58
IRF-5P68 inhibits TLR-mediated endogenous IRF-5 target gene expression
###end title 58
###begin p 59
###xml 128 132 128 132 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 140 143 140 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 417 421 417 421 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 429 432 429 432 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 477 486 477 486 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 4A&#8211;C</bold>
###xml 477 486 477 486 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g004"><bold>Fig. 4A&#8211;C</bold></xref>
###xml 523 527 523 527 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IKBA</italic>
###xml 532 536 532 536 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLIP</italic>
###xml 713 720 713 720 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 4D</bold>
###xml 713 720 713 720 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g004"><bold>Fig. 4D</bold></xref>
To examine the physiological function of IRF-5P68 in TLR-IRF-5 signalling, we measured the TLR-induced expression of endogenous IL12p40 and IL6 genes in RAW264.7 cells. To do so, we generated RAW264.7 cell lines stably expressing GFP or GFP-tagged IRF-5P68 and then stimulated the cells with TLR4 ligand LPS, TLR7 ligand R837 or TLR9 ligand CpG ODN1668. RT-PCR analysis revealed that TLR-ligand-induced expression of IL12p40 and IL6 was abrogated in IRF-5P68 expressing cells (Fig. 4A-C), whereas, for other genes, such as IKBA and FLIP, for which IRF-5 was not required for mRNA induction, the mRNA induction levels, in response to TLR7-ligand stimuli, remained the same as those in control RAW264.7 cell lines (Fig. 4D). Because the latter genes depend on NF-kappaB transcription factor, our results revealed that the TLR-NF-kappaB signalling pathway was not affected by IRF-5P68, at least under our experimental conditions.
###end p 59
###begin title 60
Mutated form of IRF-5 (P68) represses TLR-mediated IL6 and IL12 P40 induction.
###end title 60
###begin p 61
###xml 36 39 36 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL6</italic>
###xml 52 56 52 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IL12</italic>
###xml 68 72 68 72 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">FLIP</italic>
###xml 89 93 81 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">IKBA</italic>
###xml 172 177 164 169 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">GAPDH</italic>
RT-PCR of transcripts encoding IL6 (IL6), IL12 P40 (IL12P40), FLIP (FLIP), IkappaBalpha (IKBA) or GAPDH (encoding glyceraldehyde phosphate dehydrogenase (loading control); GAPDH) in RAW264.7 cells transduced with retroviral vector encoding GFP, GFP-IRF-5(wt) or GFP-IRF-5p68 and treated (time, above lanes) with TLR4 ligand LPS (A), TLR7 ligand R837 (B and d) or TLR9 ligand ODN (C). Data are representative of three independent experiments.
###end p 61
###begin p 62
###xml 116 122 116 122 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 5</bold>
###xml 116 122 116 122 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g005"><bold>Fig. 5</bold></xref>
We next measured TLR-ligand induced production of IL12p40 and IL6 by enzyme-linked immunosorbent assay. As shown in Fig. 5, the IRF-5P68 expressing RAW264.7 cells produced much less IL12p40 and IL6 in response to TLR4, TLR7 and TLR9-ligand induction than did control RAW264.7 cell lines. These results collectively demonstrate that IRF-5P68 functions as a negative regulator by specifically targeting IRF-5.
###end p 62
###begin title 63
Mutated form of IRF-5 (P68) represses LPS- and R873-mediated IL6 and IL12 P40 production.
###end title 63
###begin p 64
ELISA of IL6 or IL12 P40 in RAW264.7 cells transduced with retroviral vector encoding GFP (vector) or GFP-IRF-5P68 (P68) and then 'mock-stimulated' (control) or stimulated with TLR4 ligand LPS (A), TLR7 ligand R837 (B and D) or TLR9 ligand ODN (C). Data represent the mean +/- s.d. of three experiments.
###end p 64
###begin title 65
Discussion
###end title 65
###begin p 66
###xml 130 138 <span type="species:ncbi:9606">patients</span>
In this study, we have characterized a mutated form of IRF-5 in tumor or transformed B and T cell lines and in PBMCs derived from patients suffering from ATL or CLL. This is the first report linking IRF-5 mutation to certain malignant diseases, although previous studies using genetic methods have associated IRF-5 to the development of autoimmune diseases such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Our study demonstrates that this mutation dominant-negatively regulates the transactivation activity of wild type IRF-5 through formation of IRF-5-IRF-5P68 heterodimers.
###end p 66
###begin p 67
###xml 190 196 183 189 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Fig. 1</bold>
###xml 190 196 183 189 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pone-0005500-g001"><bold>Fig. 1</bold></xref>
###xml 198 202 191 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Fujii1">[21]</xref>
###xml 482 486 475 479 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Taniguchi1">[22]</xref>
###xml 785 789 770 774 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Fujii1">[21]</xref>
###xml 791 795 776 780 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Taniguchi1">[22]</xref>
###xml 797 801 782 786 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Escalante1">[23]</xref>
Recently, the crystal structure analysis of IRF-1 and IRF-2 reveal that IRF DNA-binding domain consists of three alpha-helices, three long loops and four stranded anti-parallel beta-sheets (Fig. 1) [21]. Given that this structure resembles the winged helix-turn-helix (HTH)-containing DNA-binding motif and its mode of protein-DNA interaction is distinct from that of other HTH-containing proteins, the IRFs are therefore characterized as a novel HTH-containing super-family member [22]. Both IRF-1 and IRF-2 use the third alpha-helix to contact the major groove of the GAAA DNA sequence, and other fragments including the three loops and the alpha-helices to contact the adjacent DNA sequence. The secondary structure of IRF-5 DNA-binding domain is similar to that of IRF-1 and IRF-2 [21], [22], [23], suggesting that IRF-5 may utilize a similar model to recognize the similar DNA sequences. In our study, the characterized mutation site of IRF-5 is positioned in the flanking site of the fourth tryptophan within the N-terminal DNA-binding domain, which is conserved among IRF family members and is harboured by the second alpha-helix. The functional analysis by EMSA and luciferase assay further shows that IRF-5P68 completely loses its DNA-binding and transactivating activities. Although the structural alteration derived from the missense point mutation eradicates the DNA binding activity of IRF-5P68, it does not remarkably alter other protein properties because this mutant like its wild type predominantly localizes in the cytosol and dynamically shuttles between cytoplasm and nucleus in resting cells.
###end p 67
###begin p 68
###xml 589 597 589 597 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Table S1</bold>
###xml 589 597 589 597 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005500.s001"><bold>Table S1</bold></xref>
###xml 1068 1077 1068 1077 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Figure S1</bold>
###xml 1068 1077 1068 1077 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pone.0005500.s002"><bold>Figure S1</bold></xref>
###xml 1648 1652 1648 1652 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Sharma1">[24]</xref>
###xml 1816 1820 1816 1820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Scott1">[25]</xref>
###xml 1822 1826 1822 1826 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Mattick1">[26]</xref>
###xml 1828 1832 1828 1832 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Nishikura1">[27]</xref>
###xml 0 5 <span type="species:ncbi:9606">Human</span>
###xml 477 485 <span type="species:ncbi:9606">patients</span>
Human genome analysis shows that the mutation site of IRF-5P68 is located within Exon 3 adjacent to its 5' end in the region of chromosome 7q32.1. Based on this information, we consulted the NCBI database for Single Nucleotide Polymorphorisms (SNPs). Unexpectedly, no SNPs in relation to this mutation site are presented in the database. We then sequenced the Exon 3 of IRF-5 gene using the genomic DNA isolated from previously described cell lines and PBMCs obtained from CLL patients carrying the mutated transcripts. Intriguingly, the mutation is undetectable at the genomic DNA level (Table S1), which suggests that the point mutation does not result from SNPs. To explore the molecular mechanism of this mutagenesis further, we employed the Restriction Fragment Length Polymorphorism (RFLP) method by southern-blot assay. By using Exon 3 DNA sequence as probe, a roughly 10 kb fragment was unexpectedly detected in the genomic DNA extracted from Jurkat cell line, which carries IRF-5 mutant transcripts, but not in MT4 cell line without IRF-5 mutant transcripts (Figure S1). In addition, the RFLP analysis by checking enzymatic cutting sites of IRF-5 pseudogene, located in chromosome 8q22.1 (pseudogene.org ID: 239282), was unable to give rise to a 10 kb fragment. These results indicate that the novel 10 kb fragment may not come from IRF-5 pseudogene but from IRF-5 gene amplification or chromosomal recombination. It will be of great interest to determine whether the IRF-5P68 mutation is associated with IRF-5 gene amplification or rearrangement. It has been demonstrated that RNA editing enzymes are also involved in mRNA point mutation [24]. The RNA editing enzymes consists of the adenosine deaminases that act on RNA (ADAR) family and the apolipoprotein B editing catalytic polypeptide (APOBEC) family [25], [26], [27], but none of them is reported to participate in G to C mRNA editing, suggesting that the IRF-5 mutation we found is unlikely caused by RNA editing.
###end p 68
###begin p 69
###xml 269 271 269 271 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Rb</italic>
###xml 284 287 284 287 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 394 398 394 398 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Abbott1">[28]</xref>
###xml 400 405 400 405 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">irf-5</italic>
###xml 541 544 541 544 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 544 548 544 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Barnes3">[15]</xref>
###xml 567 570 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p53</italic>
###xml 635 638 635 638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Hu1">[6]</xref>
###xml 718 723 718 723 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">irf-5</italic>
###xml 821 824 821 824 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Yanai1">[3]</xref>
###xml 871 876 871 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">irf-5</italic>
Mutagenesis resulting in functional ablation of tumor suppressor genes is a molecular mechanism common in malignant cells to circumvent tightly controlled proliferative and survival system of mammalians. It has been well documented that the frequent loses of copies of Rb, especially p53 genes in CLL contribute to disease progression, poor response to chemotherapy and poor prognostic outcome [28]. irf-5 has been characterized as a tumor suppressor gene and the growth inhibition mediated by IRF-5 is underlined in a manner independent on p53[15]. IRF-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death [6]. In addition, DNA damaging reagents can induce IRF-5 nuclear accumulation, and irf-5 is also associated with the stimulation of multiple cell cycle regulatory and proapoptotic genes [3]. These observations indicate that mutation of irf-5 might be a molecular mechanism employed by malignant cells to achieve the capacity of survival or proliferation, and protecting themselves from killing by chemotherapeutical treatment. On the other hand, the discovery of an IRF-5 mutation lacking transactivation activity in ATL and CLL may unveil a clue that the transactivation activity of IRF-5 might play an essential role in its function as a turmor suppressor.
###end p 69
###begin p 70
###xml 133 137 133 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Ochsenbein1">[29]</xref>
###xml 139 143 139 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Spaner1">[30]</xref>
###xml 353 357 353 357 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Spaner2">[31]</xref>
###xml 533 537 533 537 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Decker1">[32]</xref>
###xml 830 834 830 834 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Negishi1">[17]</xref>
###xml 893 897 893 897 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Martin1">[33]</xref>
###xml 746 764 <span type="species:ncbi:10376">Epstein-Barr virus</span>
###xml 934 942 <span type="species:ncbi:9606">patients</span>
Furthermore, weak immunogenicity of CLL cells may contribute to disease progression and inhibit the effectiveness of immunotherapies [29], [30]. It has been demonstrated that in response to TLR7 activation, CLL cells increase costimulatory molecular expression, produce inflammatory cytokines and become more sensitive to killing by cytotoxic effectors [31]. Similarly, costimulation of CLL with TLR9-ligand CpG-ODN and CD40-ligand CD40LF strongly increases in inflammatory cytokine production and costimulatory molecular expression [32]. IRF-5 is a key player of TLR7/TLR9 signalling and is involved in tumor cell growth and apoptosis. The important role of IRF-5 in cell growth control is also emphasized in naive primary B cells, in which the Epstein-Barr virus induces the negative regulators of IRF-5, the IRF-5v12 and IRF-4 [17], to neutralize TLR7 ligand-induced cell growth inhibition [33]. Thus, the mutation of IRF-5 in CLL patients may affect disease progression and immunotherapies through compromising IRF-5 transactivation activity.
###end p 70
###begin p 71
###xml 68 73 68 73 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Irf-5</italic>
###xml 195 199 195 199 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pone.0005500-Couzinet1">[34]</xref>
###xml 46 50 <span type="species:ncbi:10090">mice</span>
In addition, recent in vivo studies utilizing mice deficient in the Irf-5 gene have also characterized IRF-5 as a key component of death-receptor-induced apoptosis in a cell-type-specific manner [34]. IRF-5 is implicated in a stage of Fas (CD95/APO-1/TNFRSF6) signalling upstream of caspase 8 and c-jun N-terminal kinase (JNK). However, the activation of Fas receptor is not capable of inducing IRF-5 nuclear accumulation. These observations therefore raise an important issue of whether IRF-5 functions as an adaptor protein or a transcriptional activator in death-receptor-induced apoptotic signalling.
###end p 71
###begin p 72
###xml 426 434 <span type="species:ncbi:9606">patients</span>
To summarize, although IRF-5P68 mutation is present in malignant hematopoietic diseases, ATL and CLL, the link between the novel IRF-5 point mutation to clinical implications, such as pathogenesis, drug resistance and prognosis, remains to be clarified. Future studies will focus on the effect of this mutation on immuno- and chemo-therapies to improve clinical diagnosis and treatment, and therefore predict the outcomes for patients suffering from hematopoietic malignant diseases such as ATL and CLL. In addition, understanding the molecular mechanism of this mutation may shed light on the development of novel tumor-suppression-gene mutation mechanisms in malignant diseases.
###end p 72
###begin title 73
Supporting Information
###end title 73
###begin p 74
###xml 192 200 <span type="species:ncbi:9606">patients</span>
Detection of Ala to Pro mutation in residue 68 of IRF-5 genome. IRF-5 exon 3 was PCR amplified from genomic DNA isolated from indicated cell lines, peripheral blood from healthy donors or CLL patients carrying IRF-5P68 transcript and cloned into Bluescript vector. The mutation of IRF-5 was determined by DNA sequencing from plasmid DNA isolated from each sample.
###end p 74
###begin p 75
(0.06 MB DOC)
###end p 75
###begin p 76
Click here for additional data file.
###end p 76
###begin p 77
###xml 521 526 <span type="species:ncbi:9606">human</span>
Southern bloting analysis of HindIII/XbaI-digested-genomic DNA from Jurkat (1) and MT4 (2) cell lines using the exon 3 of IRF-5 as probe.10 microg of genomic DNA isolated from either Jurkat (carring an IRF-5P68 mutation) or MT4 (without IRF-5 mutation) cell lines were digested with Hind III and Xba I, separated by 0.8% agarose gel electrophoresis, transferred to nitrocellulose membranes by upward capillary transfer in 20x saline-sodium citrate (SSC) overnight, and then hybridized to the radiolabeled whole exon 3 of human irf-5 isoform a (48% formamide, 10% dextran sulfate, 5x SSC, 1x Denhardt's solution, and 100 microg/ml salmon sperm DNA) at 42degreesC overnight. The membranes were washed in 2x SSC containing 0.1% SDS for 15 min at room temperature with rotation and then in 0.1% SSC containing 0.1% SDS for another 15 min at 60degreesC. The autoradiograms were prepared using Kodak BioMax film at -80degreesC with intensifying screens.
###end p 77
###begin p 78
(3.52 MB TIF)
###end p 78
###begin p 79
Click here for additional data file.
###end p 79
###begin p 80
The authors wish to thank Nazli Azimi, Keiko Ozato, Xiuying Bai, Moutih Rafei and Michel Goldman for reagents used in this study and members of the Molecular Oncology Group, Lady Davis Institute for helpful discussions.
###end p 80
###begin title 81
References
###end title 81
###begin article-title 82
The IRF family transcription factors in immunity and oncogenesis.
###end article-title 82
###begin article-title 83
Convergence of the NF-kappaB and IRF pathways in the regulation of the innate antiviral response.
###end article-title 83
###begin article-title 84
Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression.
###end article-title 84
###begin article-title 85
###xml 31 37 <span type="species:ncbi:10090">murine</span>
Functional characterization of murine interferon regulatory factor 5 (IRF-5) and its role in the innate antiviral response.
###end article-title 85
###begin article-title 86
Integral role of IRF-5 in the gene induction programme activated by Toll-like receptors.
###end article-title 86
###begin article-title 87
Signaling through IFN regulatory factor-5 sensitizes p53-deficient tumors to DNA damage-induced apoptosis and cell death.
###end article-title 87
###begin article-title 88
virus-specific activation of a novel interferon regulatory factor, IRF-5, results in the induction of distinct interferon alpha genes.
###end article-title 88
###begin article-title 89
Multiple regulatory domains of IRF-5 control activation, cellular localization, and induction of chemokines that mediate recruitment of T lymphocytes.
###end article-title 89
###begin article-title 90
Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53.
###end article-title 90
###begin article-title 91
A CRM1-dependent nuclear export pathway is involved in the regulation of IRF-5 subcellular localization.
###end article-title 91
###begin article-title 92
The interferon regulatory factor, IRF5, is a central mediator of toll-like receptor 7 signaling.
###end article-title 92
###begin article-title 93
IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors.
###end article-title 93
###begin article-title 94
Functional regulation of MyD88 activated IRF-5 by K63-linked polyubiquitination.
###end article-title 94
###begin article-title 95
Type I inteferon gene induction by the interferon regulatory factor family of transcription factors.
###end article-title 95
###begin article-title 96
Interferon regulatory factor 5, a novel mediator of cell cycle arrest and cell death.
###end article-title 96
###begin article-title 97
Selective DNA binding and association with the CREB binding protein coactivator contribute to differential activation of alpha/beta interferon genes by interferon regulatory factors 3 and 7.
###end article-title 97
###begin article-title 98
Negative regulation of Toll-like-receptor signaling by IRF-4.
###end article-title 98
###begin article-title 99
The NEMO adaptor bridges the nuclear factor-kappaB and interferon regulatory factor signaling pathways.
###end article-title 99
###begin article-title 100
Global and distinct targets of IRF-5 and IRF-7 during innate response to viral infection.
###end article-title 100
###begin article-title 101
Virus-Induced heterodimer formation between IRF-5 and IRF-7 modulates assembly of the IFNA enhanceosome in vivo and transcriptional activity of IFNA genes.
###end article-title 101
###begin article-title 102
Crystal structure of an IRF-DNA complex reveals novel DNA recognition and cooperative binding to a tandem repeat of core sequences.
###end article-title 102
###begin article-title 103
IRF family of transcription factors as regulators of host defense.
###end article-title 103
###begin article-title 104
Structure of IRF-1 with bound DNA reveals determinants of interferon regulation.
###end article-title 104
###begin article-title 105
RNA editing in the Wilms' tumor susceptibility gene, WT1.
###end article-title 105
###begin article-title 106
A place in the world for RNA editing.
###end article-title 106
###begin article-title 107
###xml 47 52 <span type="species:ncbi:9606">human</span>
RNA editing, DNA recoding and the evolution of human cognition.
###end article-title 107
###begin article-title 108
Editor meets silencer: crosstalk between RNA editing and RNA interference.
###end article-title 108
###begin article-title 109
Recent advances in chronic lymphocytic leukemia.
###end article-title 109
###begin article-title 110
Roles of tumour localization, second signals and cross priming in cytotoxic T-cell induction.
###end article-title 110
###begin article-title 111
Effect of IL-2R beta-binding cytokines on costimulatory properties of chronic lymphocytic leukaemia cells: implications for immunotherapy.
###end article-title 111
###begin article-title 112
Immunomodulatory effects of Toll-like receptor-7 activation on chronic lymphocytic leukemia cells.
###end article-title 112
###begin article-title 113
Immunostimulatory CpG-oligonucleotides cause proliferation, cytokine production, and an immunogenic phenotype in chronic lymphocytic leukemia B cells.
###end article-title 113
###begin article-title 114
###xml 62 80 <span type="species:ncbi:10376">Epstein-Barr virus</span>
Manipulation of the toll-like receptor 7 signaling pathway by Epstein-Barr virus.
###end article-title 114
###begin article-title 115
A cell-type-specific requirement for IFN regulatory factor 5 (IRF5) in Fas-induced apoptosis.
###end article-title 115
###begin p 116
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests: </bold>
Competing Interests: The authors have declared that no competing interests exist.
###end p 116
###begin p 117
###xml 0 9 0 9 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding: </bold>
Funding: This research was supported by grants from the Cancer Research Society Inc. (to R.L.) and Canadian Institutes of Health Research (to R.L. and J. H.). R.L. was supported by a FRSQ Chercheur-boursier, and J. H. by a CIHR Senior Investigator Award. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 117

